Phase 1, Double Blind, Randomized, Parallel-group, 3‑Arm, Single-dose, Comparative Pharmacokinetic Study Of Pf‑06410293 And Adalimumab Sourced From Us And Eu Administered To Healthy Male And Female Subjects

Trial Profile

Phase 1, Double Blind, Randomized, Parallel-group, 3‑Arm, Single-dose, Comparative Pharmacokinetic Study Of Pf‑06410293 And Adalimumab Sourced From Us And Eu Administered To Healthy Male And Female Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Apr 2015

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Immunological disorders; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Acronyms REFLECTIONS B538-07
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Feb 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov.
    • 23 Dec 2014 According to ClinicalTrial.gov record, planned number of patients changed from 285 to 360.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top